(MedPage Today) — Amarin Pharma has not done enough to definitively show that its generic competitor, Hikma Pharmaceuticals, is infringing on Amarin’s patents for its anti-hypertriglyceridemia drug icosapent ethyl (Vascepa), the Supreme Court…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
